Overweight kidney transplant recipients are at risk of being overdosed following standard bodyweight-based tacrolimus starting dose

Transplantation Direct

Volumn 3, Issue 2, 2017, Pages

  Andrews, Louise M ^a   De Winter, Brenda C M ^a   Tang, Jiang Tao ^b   Shuker, Nauras ^a   Bouamar, Rachida ^a   Van Schaik, Ron H N ^a   Koch, Birgit C P ^a   Van Gelder, Teun ^a   Hesselink, Dennis A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85036507330     PISSN: None     EISSN: 23738731     Source Type: Journal    
DOI: 10.1097/TXD.0000000000000644     Document Type: Article

References (27)

1. Kidney Disease: Improving Global Outcomes Transplant Work G. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant. 2009;9:S1-S155.
2. Starzl TE, Todo S, Fung J, et al. FK 506 for liver, kidney, and pancreas transplantation. Lancet. 1989;2:1000-1004.
3. Jusko WJ, Thomson AW, Fung J, et al. Consensus document: therapeutic monitoring of tacrolimus (FK-506). Ther Drug Monit. 1995;17:606-614.
4. Astellas Pharma U, Inc. PROGRAF Tacrolimus capsules, tacrolimus injection (for intravenous infusion only). 2009. .
5. Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet. 2004;43: 623-653.
6. Thervet E, Loriot MA, Barbier S, et al. Optimization of initial tacrolimus dose using pharmacogenetic testing. Clin Pharmacol Ther. 2010;87:721-726.
7. Press RR, Ploeger BA, den Hartigh J, et al. Explaining variability in tacrolimus pharmacokinetics to optimize early exposure in adult kidney transplant recipients. Ther Drug Monit. 2009;31:187-197.
8. Kausman JY, Patel B, Marks SD. Standard dosing of tacrolimus leads to overexposure in pediatric renal transplantation recipients. Pediatr Transplant. 2008;12:329-335.
9. Rodrigo E, de Cos MA, Sánchez B, et al. High initial blood levels of tacrolimus in overweight renal transplant recipients. Transplant Proc. 2005;37: 1453-1454.
10. Størset E, Holford N, Hennig S, et al. Improved prediction of tacrolimus concentrations early after kidney transplantation using theory-based pharmacokinetic modelling. Br J Clin Pharmacol. 2014;78:509-523.
11. Friedman AN, Miskulin DC, Rosenberg IH, et al. Demographics and trends in overweight and obesity in patients at time of kidney transplantation. Am J Kidney Dis. 2003;41:480-487.
12. Lafranca JA, IJermans JN, Betjes MG, et al. Body mass index and outcome in renal transplant recipients: a systematic review and metaanalysis. BMC Med. 2015;13:111.
13. Passey C, Birnbaum AK, Brundage RC, et al. Dosing equation for tacrolimus using genetic variants and clinical factors. Br J Clin Pharmacol. 2011; 72:948-957.
14. Andrews LM, Riva N, de Winter BC, et al. Dosing algorithms for initiation of immunosuppressive drugs in solid organ transplant recipients. Expert Opin Drug Metab Toxicol. 2015;11:921-936.
15. Shuker N, Bouamar R, van Schaik RH, et al. A Randomized controlled trial comparing the efficacy of CYP3A5 genotype-based with body-weightbased tacrolimus dosing after living donor kidney transplantation. Am J Transplant. 2016;16:2085-2096.
16. van Gelder T, Silva HT, de Fijter JW, et al. Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: the fixed-dose concentration-controlled trial. Transplantation. 2008;86:1043-1051.
17. Birdwell KA, Decker B, Barbarino JM, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing. Clin Pharmacol Ther. 2015;98:19-24.
18. Sawamoto K, Huong TT, Sugimoto N, et al. Mechanisms of lower maintenance dose of tacrolimus in obese patients. Drug Metab Pharmacokinet. 2014;29:341-347.
19. Polso AK, Lassiter JL, Nagel JL. Impact of hospital guideline for weightbased antimicrobial dosing in morbidly obese adults and comprehensive literature review. J Clin Pharm Ther. 2014;39:584-608.
20. Miyamoto Y, Uno T, Yamamoto H, et al. Pharmacokinetic and immunosuppressive effects of tacrolimus-loaded biodegradable microspheres. Liver Transpl. 2004;10:392-396.
21. Tang JT, Andrews LM, van Gelder T, et al. Pharmacogenetic aspects of the use of tacrolimus in renal transplantation: recent developments and ethnic considerations. Expert Opin Drug Metab Toxicol. 2016;12: 555-565.
22. Sanghavi K, Brundage RC, Miller MB, et al. Genotype-guided tacrolimus dosing in African-American kidney transplant recipients. Pharmacogenomics J. 2015.
23. Oetting WS, Schladt DP, Guan W, et al. Genomewide Association Study of Tacrolimus Concentrations in African American Kidney transplant recipients identifies multiple CYP3A5 alleles. Am J Transplant. 2016;16: 574-582.
24. Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med. 2007; 357:2562-2575.
25. Bouamar R, Shuker N, Hesselink DA, et al. Tacrolimus predose concentrations do not predict the risk of acute rejection after renal transplantation: a pooled analysis from three randomized-controlled clinical trials(†). Am J Transplant. 2013;13:1253-1261.
26. Opelz G, Döhler B. Effect on kidney graft survival of reducing or discontinuing maintenance immunosuppression after the first year posttransplant. Transplantation. 2008;86:371-376.
27. CTS Collaborative Transplant Study Newsletter 1:2014. http://www. ctstransplantorg/public/newsletters/2014/pdf/2014-1pdf.